Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDapagliflozin: where does it fit in the treatment of type 2 diabetes
Expert Opinion in Pharmacotherapy, 10/19/09
Woo VC et al. – Dapagliflozin is a sodium–glucose co–transporter 2 inhibitor that reduces hyperglycemia by inducing significant amounts of glucosuria. Clinical trials are defining the characteristics of this new class of medication and initial results are promising.
Related Articles
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Relevance Score: 90%
Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09
Relevance Score: 90%
A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Pharmacotherapy, 10/28/09
Relevance Score: 90%
Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 90%
Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09
Relevance Score: 90%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Journal of Dermatological Treatment , 12/04/09
Non-psoriatic dermatologic uses of monoclonal antibody therapy
Journal of Dermatological Treatment , 12/04/09
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09
Sponsor
Article Search
Sponsor